A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

* Pathologically documented NSCLC * Locally advanced (Stage III) or metastatic (Stage IV) NSCLC * Only one prior anti-tumor treatment regimen in the non-curative setting (i.e., 2nd-line therapy) * Only one prior anti-tumor treatment regimen in the curative setting * Progressive disease following the previous anti-tumor treatment regimen * Measurable disease by RECIST criteria * Brain metastasis must be stable and well-controlled * ECOG performance score 0-2 * All anti-tumor therapy discontinued at least 3 weeks prior to study entry * All adverse events from prior treatment are resolved or stable * Adequate hematologic, renal, and hepatic function * Females must not be pregnant * Willing to take adequate measures to prevent pregnancy * Life expectancy of at least 3 months * Able to complete the Quality of Life questionnaire * Voluntarily signed informed consent

* Greater than Grade 1 neurological findings * Allergy to sulfa medications * Previous treatment with ABT-751 or pemetrexed * Receipt of more than one investigational agent for NSCLC * Significant weight loss (\>10%) within 6 weeks of study entry * Glucose-6-phosphate dehydrogenase deficiency or porphyria * Significant systemic disease that would adversely affect participation * Class 3-4 New York Heart Association classification status * Other cancers except in situ carcinoma of the cervix, basal or squamous cell skin cancer, or any other cancer considered adequately treated and cured by the investigator